Report Image

    irritable bowel syndrome (ibs) treatment Market

    Irritable Bowel Syndrome (IBS) Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type [IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed IBS (IBS-M)], Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), and Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies)

    • Code: TIP00083698
    • The Insight Partners
    • May-2021
    • Pharmaceuticals
    • 180 Pages
    • Published
    Get Free Sample PDF
    Purchase Benefit
    • The report will aid your decision-making capability in a more rapid and time sensitive manner.
    • Facilitate decision-making by having an in-depth analysis of the historical and forecasted data for the markets.
    • Build strategies based on latest developments and trends in markets.
    • Identify and compare the key industry partners, enhance business-development avenues based on the best practices of the major competitors.
    • Understand your competitors’ business moves and plans to devise a counter strategy.
    Already Trusted By
    Accenture aranca
    BAIN BCG
    Deloitte Eaton
    ge-healthcare Hitachi
    Honeywell KPMG
    Mckinsey Medtronic
    stc sumitomo-electric